dc.contributor.author
Wintergerst, Maximilian W. M.
dc.contributor.author
Liu, Xiaoxuan
dc.contributor.author
Terheyden, Jan H.
dc.contributor.author
Pohlmann, Dominika
dc.contributor.author
Li, Jeany Q.
dc.contributor.author
Montesano, Giovanni
dc.contributor.author
Ometto, Giovanni
dc.contributor.author
Holz, Frank G.
dc.contributor.author
Crabb, David P.
dc.contributor.author
Pleyer, Uwe
dc.contributor.author
Heinz, Carsten
dc.contributor.author
Denniston, Alastair K.
dc.contributor.author
Finger, Robert P.
dc.date.accessioned
2022-08-16T07:25:14Z
dc.date.available
2022-08-16T07:25:14Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/35894
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-35609
dc.description.abstract
Most uveitis entities are rare diseases but, taken together, are responsible for 5-10% of worldwide visual impairment which largely affects persons of working age. As with many rare diseases, there is a lack of high-level evidence regarding its clinical management, partly due to a dearth of reliable and objective quantitative endpoints for clinical trials. This review provides an overview of available structural outcome measures for uveitis disease activity and damage in an anatomical order from the anterior to the posterior segment of the eye. While there is a multitude of available structural outcome measures, not all might qualify as endpoints for clinical uveitis trials, and thorough testing of applicability is warranted. Furthermore, a consensus on endpoint definition, standardization, and "core outcomes" is required. As stipulated by regulatory agencies, endpoints should be precisely defined, clinically important, internally consistent, reliable, responsive to treatment, and relevant for the respective subtype of uveitis. Out of all modalities used for assessment of the reviewed structural outcome measures, optical coherence tomography, color fundus photography, fundus autofluorescence, and fluorescein/indocyanine green angiography represent current "core modalities" for reliable and objective quantification of uveitis outcome measures, based on their practical availability and the evidence provided so far.
en
dc.subject
Outcome measure
en
dc.subject
Imaging biomarker
en
dc.subject
Instrument-based measure
en
dc.subject
Inflammatory eye diseases
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Structural Endpoints and Outcome Measures in Uveitis
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1159/000517521
dcterms.bibliographicCitation.journaltitle
Ophthalmologica
dcterms.bibliographicCitation.number
5
dcterms.bibliographicCitation.originalpublishername
Karger
dcterms.bibliographicCitation.pagestart
465
dcterms.bibliographicCitation.pageend
479
dcterms.bibliographicCitation.volume
244
dcterms.rightsHolder.note
Copyright applies in this work.
dcterms.rightsHolder.url
http://rightsstatements.org/vocab/InC/1.0/
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.note.author
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
de
refubium.note.author
This publication is shared with permission of the rights owner and made freely accessible through a DFG (German Research Foundation) funded license at either an alliance or national level.
en
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
34062542
dcterms.isPartOf.issn
0030-3755
dcterms.isPartOf.eissn
1423-0267